Be the first person to write a business review for WuXi PharmaTech (Cayman) Inc.

Xanodyne Pharmaceuticals, Inc. company develops and manufactures drugs for pain management and women's health. Its commercial offerings include pain treatments Darvocet, Roxicodone, and Oramorph SR, as well as Duet prenatal vitamins. Zipsor, a treatment for mild to moderate inflammatory pain such as arthritic pain, and Lysteda, a treatment for menorrhagia (excessive menstrual bleeding), were both approved by the FDA in 2009. Xanodyne has several other drugs in development, including one for mild to moderate pain in late-stage clinical trials. The company funds its development efforts through sales of its commercial products, which are marketed through an internal sales force.

XTL Biopharmaceuticals Ltd. (XTL) is a biopharmaceutical company engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs, particularly the treatment of multiple myeloma (MM) and hepatitis C. The Company’s lead compound is Recombinant Erythropoietin (rHuEPO), a known compound that it is developing for the prolongation of MM patients' survival and improvement of their quality of life. MM is a severe and incurable malignant hematological cancer of plasma cells. XTL’s second program is the Diversity Oriented Synthesis program (DOS), which is focused on the development of pre-clinical hepatitis C small molecule inhibitors, which the Company had out-licensed to Presidio Pharmaceuticals, Inc. (Presidio), which is a private specialty pharmaceutical company on March 20, 2008.

ZARS Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing topically administered drugs using its proprietary drug delivery technologies, primarily in the area of pain management. It is developing a portfolio of proprietary products and product candidates based on its Controlled Heat-Assisted Drug Delivery and phase-changing cream technologies. The company’s products include Pliaglis, a topical anesthetic cream for dermal anesthesia prior to painful cosmetic procedures, such as laser surgery and dermal filler injections; and Synera, a topical patch for providing dermal analgesia for potentially painful superficial procedures, such as venous access procedures involving needles and immunization injections of children. Its products also comprise ThermoProfen, which is entering into Phase 3 clinical trials for the treatment of mild to moderate chronic pain associated with osteoarthritis of the knee; and Ketoprofen DuraPeel, a Phase 1 clinical trial product for the treatment of acute musculoskeletal pain resulting from soft tissue injuries, such as muscle strains, ankle sprains, and sports injuries. In addition, the company is developing the Alprazolam Patch, which is in Phase 1 clinical trial, for the treatment of panic disorder. The company was formerly known as ZARS, Inc. and changed its name to ZARS Pharma, Inc. in July, 2007. The company was founded in 1996 and is based in Salt Lake City, Utah.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.